One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects

Figures & data

Figure 1 Self-reported adherence rates at different time points (T expressed in months) according to the specific recall periods and eventual dosing timing.

Notes: The Y axis represents the indication on the VAS scale and can be regarded as a percentage. Data are expressed as means and 95% confidence intervals.

Figure 2 Baseline proportion of patients indicating the presence of specific symptoms possibly related to HAART. All symptoms were actively investigated by means of a structured questionnaire and patients were asked to grade the discomfort each symptom caused (VAS scale).

Figure 3 Influence of the presence and number of symptoms possibly related to HAART on the perception of health status at baseline. Box-plot analysis reporting median, interquartile range, 95% CI and outliers.

Abbreviation: AEs, adverse events.

Figure 4 Variation of quality of life over time.

Note: Dots represent mean reported values and bars 95% confidence intervals.
Abbreviation: QoL, quality of life.

Figure 5 Influence of quality of life on adherence. Box-plot analysis reporting median, interquartile range, and outliers.

Abbreviation: QoL, quality of life.

Figure 6 Patients’ preferences. Patients’ opinion was significantly in favor of the fixed dose combination (FDC) compared to the use of single drug pills (T0).

Note: Statistics refers to differences observed during the FDC use (from 1 month versus 6 months after the switch).

Figure 7 Immunolgic response (panel A) and virologic response (panel B). CD4 cell counts are expressed as means, while virologic outcome indicates the proportion of subjects below a determined threshold.